Gland Pharma to leverage Fosun ’s strengths for growth

Biologics and biosimilar drugs are emerging hotspots, and Gland is arming itself to take a leap in this segment, which is estimated to be the around $30 billion globally.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news